Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
GE blueprints $165M biologics facilities; Tarveda to partner with Madrigal in $163M deal
9 years ago
News Briefing
Sarepta rockets up after FDA approves its controversial Duchenne drug
9 years ago
Pharma
Scoop: J&J confirms that the FDA put AML drug on complete hold
9 years ago
R&D
Benitec’s abandoned one-dose hep C “cure” actually had two big problems
9 years ago
R&D
Lead vaccine from Vical and Astellas flops in a Phase II herpes study
9 years ago
R&D
Amgen’s expectations for romosozumab take a hit as Radius lines up its rival osteoporosis drug
9 years ago
R&D
Novartis shows a hole card in a high-stakes PhIII poker game for MS drugs
9 years ago
R&D
Amgen partners with Genenta, San Raffaele on an anti-tumor drug
9 years ago
News Briefing
Thumbs Up/Thumbs Down: The UN fumbles badly over access to drugs while developers think again about R&D strategies
9 years ago
Bioregnum
Opinion
Novo’s big reveal: GLP-1 drug semaglutide cuts cardio risks, but just may blind you
9 years ago
R&D
An acquisitive Celgene looks ready to pop a new multiple myeloma deal
9 years ago
Deals
Amgen, Novartis celebrate promising migraine data, but Teva and Alder are preparing to crash the party
9 years ago
R&D
The gamma delta T cell gambit inspires a small London biotech startup with big ideas
9 years ago
Startups
Novavax shares are routed after its big PhIII RSV vaccine trial flops
9 years ago
R&D
IPO-bound Intarcia hauls in $215M, and plans to add more; Peloton raises $52M round
9 years ago
News Briefing
Aralez finally gets an FDA OK for its cardio drug Yosprala, starts hiring sales reps
9 years ago
Pharma
Merck, Pfizer tout PhIII diabetes data as ertuglifozin heads to the FDA
9 years ago
R&D
Rigel co-founder, R&D staff jettisoned in the long-awaited lead up to an FDA pitch
9 years ago
R&D
Eisai launches biotech division in Massachusetts aimed at Alzheimer’s, I/O and autoimmune diseases
9 years ago
R&D
AcelRx takes another step in its recovery program, prepping a pain med pitch to the FDA
9 years ago
R&D
Aerie shares rocket up as glaucoma combo drug scores positive data
9 years ago
R&D
Agios sets out to raise $150M; AC Immune IPO sets valuation at $700M
9 years ago
R&D
News Briefing
The FDA confirms that Sarepta nemesis Ronald Farkas has left the agency
9 years ago
Pharma
Roche’s megablockbuster MS candidate ocrelizumab posts promising head-to-head data
9 years ago
R&D
First page
Previous page
1164
1165
1166
1167
1168
1169
1170
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit